Rhythm Pharmaceuticals Inc
Company Profile
Business description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Contact
222 Berkeley Street
12th Floor
BostonMA02116
USAT: +1 857 264-4280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
414
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
stocks
A look into newly listed Glencore’s valuation
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,838.49 | 29.56 | -0.38% |
| DAX 40 | 25,304.42 | 15.35 | -0.06% |
| Dow JONES (US) | 52,495.88 | 529.85 | 1.02% |
| FTSE 100 | 10,733.00 | 31.69 | -0.29% |
| HKSE | 23,714.60 | 153.14 | -0.64% |
| NASDAQ | 26,424.82 | 6.07 | -0.02% |
| Nikkei 225 | 64,676.93 | 601.51 | 0.94% |
| NZX 50 Index | 13,761.29 | 129.60 | 0.95% |
| S&P 500 | 7,712.57 | 21.84 | 0.28% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,717.17 | 18.20 | -0.49% |